164 related articles for article (PubMed ID: 33191818)
1. Link between serum uric acid and pancreatic beta-cell function in drug naïve subjects with type 2 diabetes treated with sitagliptin.
Kutoh E; Wada A; Kuto AN; Hayashi J; Kurihara R
Hosp Pract (1995); 2021 Apr; 49(2):71-78. PubMed ID: 33191818
[No Abstract] [Full Text] [Related]
2. REGULATION OF FREE FATTY ACID BY SITAGLIPTIN MONOTHERAPY IN DRUG-NAÏVE SUBJECTS WITH TYPE 2 DIABETES.
Kutoh E; Wada A; Hayashi J
Endocr Pract; 2018 Dec; 24(12):1063-1072. PubMed ID: 30289315
[TBL] [Abstract][Full Text] [Related]
3. Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes.
Kutoh E; Murayama T; Wada A; Hirate M
Drugs R D; 2016 Dec; 16(4):369-376. PubMed ID: 27798769
[TBL] [Abstract][Full Text] [Related]
4. Sitagliptin as an Initial Therapy and Differential Regulations of Metabolic Parameters Depending on its Glycemic Response in Subjects with Type 2 Diabetes.
Kutoh E; Kuto AN; Wada A; Hayashi J; Kurihara R
Drug Res (Stuttg); 2021 Mar; 71(3):157-165. PubMed ID: 33241550
[TBL] [Abstract][Full Text] [Related]
5. Teneligliptin, a Chemotype Prolyl-Thiazolidine-Based Novel Dipeptidyl Peptidase-4 Inhibitor with Insulin Sensitizing Properties.
Kutoh E; Wada A; Terayama S
Clin Drug Investig; 2016 Oct; 36(10):809-18. PubMed ID: 27352309
[TBL] [Abstract][Full Text] [Related]
6. Alogliptin: a DPP-4 inhibitor modulating adipose tissue insulin resistance and atherogenic lipid.
Kutoh E; Kuto AN; Akiyama M; Ozawa E; Kurihara R
Eur J Clin Pharmacol; 2023 Jul; 79(7):947-959. PubMed ID: 37193913
[TBL] [Abstract][Full Text] [Related]
7. Two Glucose-Lowering Mechanisms of Canagliflozin Depending on Body Weight Changes in Drug-Naïve Subjects with Type 2 Diabetes.
Kutoh E; Wada A; Murayama T; Hayashi J
Drugs R D; 2018 Dec; 18(4):309-315. PubMed ID: 30324549
[TBL] [Abstract][Full Text] [Related]
8. Regulations of Free Fatty Acids and Diabetic Parameters in Drug Naïve Subjects with Type 2 Diabetes Treated with Canagliflozin Monotherapy.
Kutoh E; Kuto AN; Wada A; Kurihara R; Kojima R
Drug Res (Stuttg); 2022 Feb; 72(2):86-93. PubMed ID: 34729722
[TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl peptidase-4 inhibitor sitagliptin improves pancreatic β-cell function in hypertensive diabetic patients treated with angiotensin receptor blockers.
Fukui K; Kawahito H; Wakana N; Kikai M; Terada K; Yamamoto K; Irie D; Kato T; Miyagawa S; Yamada H
J Renin Angiotensin Aldosterone Syst; 2015 Dec; 16(4):1001-9. PubMed ID: 26195265
[TBL] [Abstract][Full Text] [Related]
10. Effects of sitagliptin on circulating zinc-α2-glycoprotein levels in newly diagnosed type 2 diabetes patients: a randomized trial.
Tian M; Liang Z; Liu R; Li K; Tan X; Luo Y; Yang M; Gu HF; Liu H; Li L; Yang G
Eur J Endocrinol; 2016 Feb; 174(2):147-55. PubMed ID: 26546612
[TBL] [Abstract][Full Text] [Related]
11. Distinct glucose-lowering properties in good responders treated with sitagliptin and alogliptin.
Kutoh E; Hirate M; Wada A
Int J Clin Pract; 2015 Nov; 69(11):1296-302. PubMed ID: 26194442
[TBL] [Abstract][Full Text] [Related]
12. Regulation of serum uric acid with canagliflozin monotherapy in type 2 diabetes: A potential link between uric acid and pancreatic β-cell function
.
Kutoh E; Wada A; Kuto AN; Hayashi J
Int J Clin Pharmacol Ther; 2019 Dec; 57(12):590-595. PubMed ID: 31587751
[TBL] [Abstract][Full Text] [Related]
13. Diverse Strategies for Modulating Insulin Resistance: Causal or Consequential Inference on Metabolic Parameters in Treatment-Naïve Subjects with Type 2 Diabetes.
Kutoh E; Kuto AN; Okada R; Akiyama M; Kurihara R
Medicina (Kaunas); 2024 Jun; 60(6):. PubMed ID: 38929608
[No Abstract] [Full Text] [Related]
14. Alogliptin: a new dipeptidyl peptidase-4 inhibitor with potential anti-atherogenic properties.
Kutoh E; Kaneoka N; Hirate M
Endocr Res; 2015; 40(2):88-96. PubMed ID: 25208188
[TBL] [Abstract][Full Text] [Related]
15. Modulating impacts of quercetin/sitagliptin combination on streptozotocin-induced diabetes mellitus in rats.
Eitah HE; Maklad YA; Abdelkader NF; Gamal El Din AA; Badawi MA; Kenawy SA
Toxicol Appl Pharmacol; 2019 Feb; 365():30-40. PubMed ID: 30576699
[TBL] [Abstract][Full Text] [Related]
16. Regulation of Adipose Tissue Insulin Resistance and Diabetic Parameters in Drug Naïve Subjects with Type 2 Diabetes Treated with Canagliflozin Monotherapy.
Kutoh E; Kuto AN; Ozawa E; Kurihara R; Akiyama M
Drug Res (Stuttg); 2023 Jun; 73(5):279-288. PubMed ID: 36882112
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy of sitagliptin as either monotherapy or add-on therapy to metformin: improvement in glycemic control over 2 years in patients with type 2 diabetes.
Katzeff HL; Williams-Herman D; Xu L; Golm GT; Wang H; Dong Q; Johnson JR; O'Neill EA; Kaufman KD; Engel SS; Goldstein BJ
Curr Med Res Opin; 2015 Jun; 31(6):1071-7. PubMed ID: 25850968
[TBL] [Abstract][Full Text] [Related]
18. Short and Long Term Effects of a DPP-4 Inhibitor Versus Bedtime NPH Insulin as ADD-ON Therapy in Patients with Type 2 Diabetes.
da Silva GM; Nogueira KC; Fukui RT; Correia MR; Dos Santos RF; da Silva ME
Curr Pharm Des; 2016; 22(44):6716-6721. PubMed ID: 27928958
[TBL] [Abstract][Full Text] [Related]
19. Effect of Pioglitazone on Serum Uric Acid Levels in Newly Diagnosed, Drug-Naïve Patients with Type 2 Diabetes.
Kutoh E; Hori T
Endocr Res; 2013 Aug; 38(3):151-159. PubMed ID: 23216460
[TBL] [Abstract][Full Text] [Related]
20. Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin.
Derosa G; Carbone A; D'Angelo A; Querci F; Fogari E; Cicero AF; Maffioli P
Intern Med; 2013; 52(19):2179-87. PubMed ID: 24088749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
